C&SR

Name

C&SR

Legal name

주식회사 씨앤에스알

Website

https://cnsr.co.kr

Company type

Private

Founded year

2022

Operating status

Operating

Ownership category

akta.pro rank

Product category

Preclinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

akta.pro secondary industry

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

Keywords

• Humanized mouse models
• Preclinical drug evaluation
• Disease model development
• CDX PDX xenograft services
• Human immune system research

Headquarters

HQ city

Uiwang

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. R&D Services and Disease Model Development: Custom disease model development and evaluation services for pharmaceutical and biotech companies. Provides humanized mouse models and related testing/evaluation services.
2. Humanized Mouse Models: Sale of specialized humanized mice including Mirroring Mouse™ and Shadow Mouse™ platforms for drug efficacy and safety testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

C&SR develops and supplies advanced humanized mouse models and related R&D services for preclinical drug evaluation. Its two proprietary platforms — Shadow Mouse™ (short-term PBMC-based) and Mirroring Mouse™ (long-term CD34+ cord blood-derived) — combined with a proprietary immune-boosting technology, achieve 80–98% human CD45+ immune cell engraftment and survival exceeding 40 weeks. On top of these platforms, the company layers disease-specific models (CDX/PDX oncology, infectious, respiratory, metabolic, urogenital, neurological, autoimmune) along with custom disease model development and evaluation consulting.

Product overview

C&SR's offering is a platform-plus-modules architecture built around two proprietary humanized mouse platforms — Shadow Mouse™ (short-term PBMC-based evaluation) and Mirroring Mouse™ (long-term CD34+ cord blood-derived persistent evaluation) — supported by a proprietary immune-boosting technology that achieves 80-98% human CD45+ immune cell reconstitution and survival exceeding 40 weeks. The platforms serve as a core biotech research substrate on top of which the company layers multiple disease-specific model modules: CDX/PDX oncology models, infectious disease models (HIV, SARS-CoV-2), respiratory disease models (asthma, lung injury, fibrosis), metabolic disease models (obesity, diabetes, fatty liver), urogenital disease models (nephritis, kidney disease), neurological disease models (Parkinson's, stroke, spinal cord injury), and autoimmune disease models (SLE, MS, rheumatoid arthritis). Custom consulting and assay services complete the offering.

Differentiator

Problem solved

Functional benefit

Brands

• Mirroring Mouse™: Long-term evaluable persistent humanized mouse model using cord blood-derived CD34 positive hematopoietic stem cells
• Shadow Mouse™

Products and services

• Mirroring Mouse™ Platform Long-term evaluable humanized mouse model built using cord blood-derived CD34+ hematopoietic stem cells, maintaining 80–98% human CD45+ immune cell reconstitution and survival exceeding 40 weeks; used as the core backbone for C&SR's disease modeling services.
• Shadow Mouse™ Platform Short-term evaluation humanized mouse model built using peripheral blood mononuclear cell (PBMC) transplantation, providing rapid immunological assessment for early-stage drug efficacy screening.
• Human Stem Cell Transplantation & Immune Boosting Technology Proprietary technology that achieves 80–98% human CD45+ immune cell reconstitution and 40+ week survival through immune cell-specific boosting, enabling precise control of mouse immune cells while maintaining high human immune cell levels.
• Disease Model Development & Evaluation Services Custom disease model development and evaluation services for pharmaceutical, biotech, academic, and CRO customers, including experimental consulting, animal model construction, and assay services tailored to specific research objectives.

Quantifiable outcome

• 80-98% human CD45+ cell engraftment rate
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core.

• 주식회사 씨앤에스알-젬크로-케이더블유바이오 (C&SR-Gemkro-KDW Bio)coreStrategic or Co-development Partner · 1 March 2025Trilateral MOU for domestic humanized model development among three Korean biotech companies, signed March 2025.
• 주식회사 이뮤니스바이오 (Immunis Bio)coreStrategic or Co-development Partner · 1 March 2025MOU for responding to implementation decree of the 'Subsequent Act' (첨생법), signed March 2025.
• 주식회사 에이치엘비바이오코드 (HLBioCode)coreStrategic or Co-development Partner · 1 July 2024MOU for expanding humanized mouse-based research domain strategies, signed July 2024.
• 주식회사 자바이오 (Jabio)coreStrategic or Co-development Partner · 1 July 2024MOU for developing disease models based on severe immunodeficiency mice, signed July 2024.
• 주식회사 디티앤씨알오 (DTN CRO)coreStrategic or Co-development Partner · 1 May 2024MOU for humanized mouse technology cooperation, signed May 2024.
• 주식회사 이온셀 (IonCell)coreStrategic or Co-development Partner · 1 March 2024MOU for establishing drug efficacy verification cooperation system, signed March 2024.
• 한국원자력의학원/원자력병원 (Korea Institute of Radiological Medicine / Radiation Hospital)coreStrategic or Co-development Partner · 1 February 2024Joint research cooperation seminar held February 2024.
• 중앙대학교 분자바이오디자인융합센터 (Chung-Ang University Molecular Bio-Design Convergence Center)coreStrategic or Co-development Partner · 1 September 2023MOU for academic-industry cooperation in molecular bio-design research, signed September 2023.
• 주식회사 엔케이맥스 (NKMAX)coreStrategic or Co-development Partner · 1 March 2023MOU for business cooperation, signed March 2023.
• 가톨릭대학교 서울성모병원-인체기능재생줄기세포연구실 (Catholic University Seoul St. Mary's Hospital Human Functional Regeneration Stem Cell Lab)coreStrategic or Co-development Partner · 1 March 2023MOU for academic-industry research cooperation, signed March 2023.
• 중앙대학교 의과대학/의학부 (Chung-Ang University College of Medicine)coreStrategic or Co-development Partner · 1 February 2023MOU for business cooperation in medical research, signed February 2023.
• 동물의료센터 아이윌24 (Animal Medical Center iWill24)coreStrategic or Co-development Partner · 1 February 2023MOU for veterinary medical cooperation, signed February 2023.
• 랩토피아 (Labtopia)coreStrategic or Co-development Partner · 1 February 2023MOU for laboratory cooperation, signed February 2023.
• 주식회사 프로큐라티오 (Procuratio)coreStrategic or Co-development Partner · 1 December 2022Joint R&D cooperation and business MOU signed December 2022.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Shanghai ChemPartner: Shanghai ChemPartner is a China-headquartered preclinical CRO providing in vivo pharmacology and disease model services. It is comparable to C&SR as a regional Asian preclinical service provider, though serving a different national customer base.
• Bionova Scientific (BPGbio / equivalent regional preclinical CRO): Bionova Scientific and similar regional preclinical CROs offer humanized mouse-based in vivo efficacy and safety services to pharma and biotech. They are relevant comparables for C&SR's positioning in the Asian preclinical services landscape.

Broad incumbents

• Inotiv: Inotiv is a preclinical CRO offering animal model services, including toxicology and efficacy studies. It competes for the same pharma R&D services wallet as C&SR at a larger scale across multiple geographies.
• The Jackson Laboratory: The Jackson Laboratory is a leading non-profit provider of immunodeficient and humanized mouse models (e.g., NSG, NRG) used as the substrate for humanization. C&SR's Mirroring Mouse™/Shadow Mouse™ are competing humanized alternatives built on similar background strains.
• Charles River Laboratories: Charles River offers end-to-end preclinical CRO services, including humanized mouse efficacy/safety studies. C&SR competes for the same pharma R&D services budget, though Charles River operates at much larger scale and geographic breadth.
• WuXi AppTec (WuXi Biologics / WuXi STA): WuXi AppTec provides integrated preclinical and clinical R&D services globally, including in vivo pharmacology and humanized model studies. C&SR is a much smaller specialist alternative for Asian biotech customers seeking humanized mouse services.

Direct peers

• Crown Bioscience (JSR Life Sciences): Crown Bioscience operates one of the largest commercial humanized mouse and PDX/CDX model portfolios for preclinical oncology and immuno-oncology drug development. C&SR competes for the same Korean and Asian pharma customers seeking humanized mouse preclinical services.
• Taconic Biosciences: Taconic commercializes humanized immune system mouse models and supporting preclinical services for biopharma. C&SR targets the same humanized mouse buyer in drug efficacy and safety testing.

Emerging players

• GenOway: GenOway is a specialist in custom humanized and transgenic mouse model development and licensing for preclinical research. C&SR overlaps directly on humanized mouse platform technology and disease model generation.
• Cyagen Biosciences: Cyagen is a China-based provider of custom mouse models, including humanized mouse platforms, for biomedical research. It is a comparable emerging specialist in humanized mouse model generation and licensing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C&SR